Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
41.24
+0.65 (+1.60%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
30
31
Next >
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
May 08, 2023
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug
Via
MarketBeat
WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns
May 08, 2023
The World Health Organization ended the global emergency
Via
Benzinga
GSK: Add This Cheap Chip Play To Your Portfolio
May 06, 2023
GSK pays a decent quarterly dividend. The latest declared dividend is $0.35 per share, giving GSK a yield of 3.85%.
Via
Talk Markets
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment
May 04, 2023
From
HKTDC
Via
ACN Newswire
A Shot of Success: GSK's Arexvy Wins FDA Approval, Pioneering RSV Prevention for Older Adults in Multi-Billion Dollar Market
May 03, 2023
The FDA has approved GSK Plc's (NYSE: GSK) Arexvy (respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in...
Via
Benzinga
GSK Stock: A Value Trap or a Hidden Gem?
April 27, 2023
GSK, formerly known as GlaxoSmithKline, is struggling after a complicated earnings season. Here's why GSK stock is still a buy.
Via
InvestorPlace
GSK Clocks 10% Growth In Q1 Sales Excluding COVID-19 Products, Reaffirms Guidance
April 26, 2023
Via
Benzinga
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
May 03, 2023
From
GSK plc
Via
Business Wire
GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line
May 03, 2023
GSK won FDA approval for the first-ever RSV vaccine for older adults.
Via
Investor's Business Daily
KVUE Stock: Should You Buy Into the Kenvue IPO?
May 03, 2023
KVUE stock will be a dividend stock with an initial yield of 3.5%, with slow growth and lower margins than JNJ's drug business.
Via
InvestorPlace
Pharma Giant Pfizer To Start Selling Haleon Stake Within Months, CFO Says
May 03, 2023
Pfizer Inc (NYSE: PFE) is reportedly looking to start selling its stake in Haleon plc (NYSE: HLN).
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
May 01, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
April 28, 2023
Microsoft, Meta, Cloudflare and Crocs were among the many big movers.
Via
Investor's Business Daily
A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US
April 27, 2023
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure...
Via
Benzinga
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost?
April 27, 2023
The company reported lighter-than-expected declines due to Keytruda and Gardasil.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
April 26, 2023
Via
Benzinga
3 Biotechs That Might Get Bought Out in 2023
April 26, 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year.
Via
The Motley Fool
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls
April 26, 2023
Both GSK and Roche experienced declining Covid-related sales in the first quarter.
Via
Investor's Business Daily
Was This Acquisition a Savvy Play by This Big Pharma Stock?
April 26, 2023
The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health.
Via
The Motley Fool
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
April 25, 2023
Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
April 25, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
April 25, 2023
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
Via
The Motley Fool
Second Quarter Outlook For Biotech Stocks
April 25, 2023
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.
Via
Talk Markets
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
April 24, 2023
Via
Benzinga
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
April 21, 2023
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.
Via
Benzinga
Why Shares of Bellus Health Skyrocketed This Week
April 20, 2023
The company has received a buyout offer from GSK.
Via
The Motley Fool
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
April 18, 2023
From
BELLUS Health Inc.
Via
Business Wire
Why BELLUS Health Stock Is Rocketing Higher Today
April 18, 2023
A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today.
Via
The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
April 18, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
April 18, 2023
Shares of its takeover candidate nearly doubled on the news.
Via
Investor's Business Daily
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.